New drug LAD603 put to the test in healthy volunteers
NCT ID NCT06200597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and tolerability of a new drug, LAD603, in 92 healthy adults aged 18 to 65. Participants received either the drug or a placebo to see how the body processes it and if it causes side effects. The goal was to gather initial safety data, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON Phase 1 unit Lenexa
Lenexa, Kansas, 66219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults